Please read the trial details and requirements below. All trials are held at The Kinghorn Cancer Centre, Darlinghurst NSW. 

Contact us for further information, to see if you're eligible for treatment, or to enquire about upcoming trials. 

Claire Gray, Breast Cancer Clinical Research Nurse (Mon-Thur) 
Email: claire.gray@svha.org.au
Phone: 02 9355 5708 
Fax: 02 9355 5735

Early-stage breast cancer

OBI-822 Adagloxad Simolenin vaccine trial

A study of adjuvant Adagloxad Simolenin (novel immune-oncology vaccine) treatment for high risk early stage triple negative breast cancer.

• Requirements: early stage triple negative breast cancer (oestrogen/progesterone receptors and HER2 negative), has residual invasive disease following neoadjuvant chemotherapy or ≥4 axillary lymph node involvement and received adjuvant chemotherapy
• Reference: HREC/18/SVH/198

Prosper Study: Endopredict Genomic Assay 

A study to examine the impact of EndoPredict (genomic assay profile) on adjuvant treatment recommendations in early hormone receptor positive HER2 negative breast cancer.

• Requirements: Oestrogen receptor positive, HER2 negative early stage breast cancer following surgery, tumour less than 50mm in greatest dimension and <3 axillary lymph node involvement, no contraindication for adjuvant chemotherapy
• Reference: HREC/17/WMEAD/211

WinPro Study with prometrium (microionised progesterone)

A study of endocrine therapy with progesterone in post-menopausal women with early-stage hormone receptor positive breast cancer, prior to undergoing breast surgery.

• Requirements: post-menopausal women with early-stage breast cancer which is estrogen and progesterone receptors positive, HER2 receptor negative, a tumour size of ≥1cm and have not yet had breast surgery.
• Reference: HREC/17/SVH/255

GDC 9545 window study 

A study of endocrine therapy with GDC 9545 (selective oestrogen receptor degrader) in post-menopausal women with early-stage hormone receptor positive breast cancer, prior to undergoing breast surgery

• Requirements: post-menopausal women with early-stage breast cancer which is estrogen receptor positive, HER2 receptor negative, a tumour size of ≥1cm and have not yet had breast surgery.

NATALEE with ribociclib 

A study of endocrine therapy with ribociclib (CDK4/6 inhibitor) in patients with high-risk early-stage hormone receptor positive breast cancer following surgery. 

• Requirements: patients with high risk early-stage breast cancer which is hormone receptor positive, HER2 receptor negative and have undergone breast surgery, within 12 months of commencing adjuvant endocrine therapy.

MonarchE Study with abemaciclib (Verzenio, a CDK4/6 inhibitor)

A study of endocrine therapy with abemaciclib in patients with high-risk early-stage hormone receptor positive breast cancer following surgery.

• Requirements: patients with early-stage breast cancer with lymph node involvement which is estrogen receptor positive, HER2 receptor negative and have undergone breast surgery.

Exercise during chemotherapy study

A study of exercise during chemotherapy for breast cancer given prior to surgery (Neoadjuvant or preoperative chemotherapy). We will provide patients with a personalised exercise program and study the effects of exercise on the tumour at the time of surgery.

• Requirements: patients with early-stage breast cancer who have their chemotherapy prior to surgery.
• Reference: HREC/16/SVH/334

Impassion30 study

A study of atezolizumab immunotherapy (anti-PD1 antibody) in combination with anthracycline taxane based chemotherapy in patients with triple negative breast cancer.

• Requirements: early stage triple negative breast cancer, which is negative for the oestrogen receptor, progesterone receptor and HER2 receptor, have completed their surgery.
• Reference: HREC/18/SVH/104

Advanced breast cancer

ATTAIN study with NKTR-102 chemotherapy

A study of NKTR-102 chemotherapy for patients with advanced breast cancer who have stable brain metastases and have previously received treatment with the following chemotherapy drugs: anthracycline, taxane and capecitabine.

• Requirements: patients with advanced breast cancer with stable brain metastases that have been previously treated with radiotherapy and/or surgery, and prior chemotherapy with anthracycline, taxane and capecitabine.
• Reference: HREC/17/SVH/11

Patina study with palbociclib (Ibrance, a CDK4/6 inhibitor)

A study of palbociclib (Ibrance) with trastuzumab (Herceptin), pertuzumab (Perjeta) and endocrine therapy for patients with advanced breast cancer.

• Requirements: patients with advanced breast cancer which is estrogen and HER2 receptors positive, and have not received prior treatment for metastatic disease.
• Reference: HREC/17/SVH/141

A selective Estrogen Receptor Degrader study for ER positive breast cancer

A study of GDC-9545 alone or in combination with palbociclib (Ibrance) and goserelin (Zoladex) for advanced breast cancer.

• Requirements: patients with advanced breast cancer, which is estrogen receptor positive and HER2 receptor negative.
• Reference: HREC/17/PMCC/158

Study with abemaciclib (Verzenio, a CDK4/6 inhibitor)

A study of abemaciclib and the impact of food for advanced breast cancer.

• Requirements: Patients with advanced breast cancer, which is estrogen receptor positive and HER2 receptor negative, and have received prior hormone treatment and chemotherapy for metastatic disease
• Reference: HREC/18/SVH/199

U-301 study 

A trial of DS-8201a, an Anti-HER2-antibody drug conjugate versus treatment of investigator's choice for pretreated advanced/metastatic HER-2 positive breast cancer.

• Requirements: Unresectable or metastatic HER2 positive breast cancer, received previous standard of care HER2 therapies including T-DM1  
• Reference: HREC/19/OTHER/10

Ipatasertib study with immunotherapy

A study of ipatasertib, atezolizumab (Tecentriq, immunotherapy) and chemotherapy for advanced triple negative breast cancer.

• Requirements: patients with advanced breast cancer, which is negative for the estrogen, progesterone and HER2 receptors.
• Reference: HREC/17/PMCC/186

Atezolizumab and BET inhibitor study

A study of atezolizumab immunotherapy (anti-PD1 antibody) in combination with RO6870810 BET inhibitor drug for patients with advanced triple negative breast cancer.

• Requirements: advanced breast cancer, which is negative for the oestrogen receptor, progesterone receptor and HER2 receptor.
• Reference: HREC/18/PMCC/138

All patients undergoing breast surgery at St Vincent’s Hospital

Project SHARE (Specimens Help All Research Efforts)

We invite all patients undergoing breast surgery at St Vincent’s Hospital to partner with us in our research endeavours. Tissue that is routinely collected at the time of surgery and in excess of diagnostic requirements will be brought to the laboratories at the Garvan Institute, enabling many researchers use these tissues as building blocks for their research.